Not Yet RecruitingNot Applicable

Effect of Immersive Virtual Reality Cognitive Rehabilitation on Subacute Stroke Patients (A Pilot Study)

Indonesia22 participantsStarted 2026-04-15

Plain-language summary

This pilot randomized controlled trial aims to evaluate the effectiveness of cognitive rehabilitation using an immersive Virtual Reality (VR) system compared to conventional paper-and-pencil cognitive training in subacute stroke patients. A total of 22 participants will be randomly assigned to either the VR intervention group (n=11) or the conventional control group (n=11). The study will measure changes in cognitive function and functional independence

Who can participate

Age range

18 Years – 59 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or female aged 40-59 years old * Stroke patient 2-4 months onset of stroke * Burnstorm stage V or above * First-time stroke that has been diagnosed by a neurologist with CT scan and/or MRI * Stroke risk factors and comorbidities are controlled with medication * Mild and moderate level of cognitive impairment based on MOCA and can use devices * Participants can grip and operate VR console with their hand * Participants can follow instructions and exercises * Participants were cooperative and willing to participate in the study by signing a consent form after receiving an explanation. Exclusion Criteria: * Participants with severe cognitive impairment or aphasia struggle to understand instructions * Neglected patient * Participants with low vision unable to perceive content on screens * Participant with eyestrain characterized by blurring vision, dry eyes, foreign body sensation, itching watering, neck stiffness and backache * Severe musculoskeletal disorders causing problem in standing and following instruction

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change in Cognitive Function Assessed by Montreal Cognitive Assessment - Indonesian Version (MoCA-INA)

Timeframe: Baseline and Post-Intervention (Week 8)

Change in Functional Activity Assessed by Functional Independence Measure (FIM)

Timeframe: Baseline and Post-Intervention (Week 8)

Trial details

NCT IDNCT07506486

SponsorUniversitas Padjadjaran

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06-30

Contact for this trial

Ani Purwati, MD

+62 852-2131-4160 anipurwati21@gmail.com

View on ClinicalTrials.gov More Stroke (Subacute) trials